AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8268648
Drug: Sequential ultrafiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential ultrafiltration (UF) with constant dialysate Na (140 mEq/L)
Trial: 8268648
Drug: Sequential ultrafiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential ultrafiltration (UF) with varying dialysate Na (150 mEq/L in the first hour, 142 in the second, and 137 in the third)
Trial: 3890131
Drug: L-carnitine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine administration (2 g i.v. three times weekly for 6 weeks)
Trial: 31409331
Drug: T33 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T33 (0.1 mg/mL, 0.5 mg/mL, 2.5 mg/mL, 5 mg/mL, 10 mg/mL)
Trial: 31409331
Drug: T33 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T33 (2.5 mg/mL, 5 mg/mL, 10 mg/mL)
Trial: 31409331
Drug: T33 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T33 (200 mg/kg and 600 mg/kg)
Trial: 27402551
Drug: ASSIST administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASSIST administered via ACASI
Trial: 24709256
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg once daily for 12 weeks with PegIFN/RBV
Trial: 24709256
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg once daily for 24 weeks with PegIFN/RBV
Trial: 24709256
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (12-week and 24-week) received identical treatment from weeks 2 to 12
Trial: 17913317
Drug: Propofol 0.5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.5mg/kg plus dexamethasone 8 mg
Trial: 15914508
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (0.8 g/kg; LP)
Trial: 15914508
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein diet (1.8 g/kg; MP)
Trial: 15914508
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (3.6 g/kg; HP)
Trial: 10229559
Drug: Iloprost i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost i.v. infusion up to 2 ng/Kg/min for 6/h/day for 28 days (Group A)
Trial: 10229559
Drug: Iloprost i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost i.v. infusion up to 1.5 ng/Kg/min for 16/h/day for 7 days (Group B)
Trial: 7913730
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of zidovudine daily
Trial: 7913730
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg of zidovudine daily
Trial: 2493733
Drug: Intravenous flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous flecainide (2 mg/kg/10 minutes)
Trial: 2493733
Drug: Verapamil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (10 mg/1 minute)
Trial: 17655565
Drug: Yoga therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga therapy (YT)
Trial: 25289715
Drug: Creatine (Cr;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (Cr; 5 g creatine plus 5 g maltodextrose)
Trial: 25289715
Drug: Beta-alanine plus
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine plus creatine (β‐ALA+Cr; 1.6 g beta alanine plus 5 g creatine plus 3.4 g maltodextrose)
Trial: 25289715
Drug: Beta-alanine (β‐ALA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (β‐ALA; 1.6 g beta alanine plus 8.4 g maltodextrose)
Trial: 25289715
Drug: Placebo (P;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P; 10 g maltodextrose)
Trial: 24239154
Drug: Standard cardiological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cardiological therapy only
Trial: 11129744
Drug: Cerebrolysin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks
Trial: 9053827
Drug: Calcium-enriched group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-enriched group (1200 mg RDA)
Trial: 9053827
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (728 mg calcium)
Trial: 1645047
Drug: Drug A
RxNorm normalized name: Drug additive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug A (original piroxicam)
Trial: 1645047
Drug: Drug B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug B (generic piroxicam)
Trial: 1645047
Drug: Drug C
RxNorm normalized name: Drug coating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug C (another generic piroxicam)
Trial: 1645047
Drug: Chronic disease
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic disease treatment
Trial: 27323902
Drug: 2 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cycles carboplatin-olaparib followed by olaparib monotherapy 300 mg BID
Trial: 27323902
Drug: Capecitabine 1250
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250 mg/m2 BID day 1-14 q day 22
Trial: 23870160
Drug: 2-dose methylprednisolone
RxNorm normalized name: methylprednisolone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose methylprednisolone (30 mg/kg per dose, given 8 hours preoperatively and operatively)
Trial: 23870160
Drug: Single-dose methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose methylprednisolone (30 mg/kg per dose, given operatively)
Trial: 23870160
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (2-dose and single-dose)
Trial: 23870160
Drug: 2-dose methylprednisolone
RxNorm normalized name: methylprednisolone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose methylprednisolone
Trial: 23870160
Drug: Single-dose methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose methylprednisolone
Trial: 23446065
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CBT + milnacipran 100 mg/d)
Trial: 21097770
Drug: Supplemental parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental parenteral glutamine
Trial: 18426835
Drug: Elevated serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated serum parathyroid hormone (PTH) levels (> or =63 ng/l, IV quartile cut point)
Trial: 18426835
Drug: Elevated serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated serum parathyroid hormone (PTH) levels after controlling for age, gender, co-morbidity, and creatinine
Trial: 12926103
Drug: YM511 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM511 0.3 mg/day
Trial: 12926103
Drug: YM511 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM511 (all doses)
Trial: 6643335
Drug: Cefoperazone 2
RxNorm normalized name: cefoperazone 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone 2 g intravenous infusion over 15 min
Trial: 29038234
Drug: Lanreotide 120
RxNorm normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 120 mg subcutaneous every 4 weeks for 16 weeks (DB)
Trial: 29038234
Drug: Lanreotide during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide during DB and IOL treatment
Trial: 29038234
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during DB and IOL treatment
Trial: 24142804
Drug: Molsidomine (Coruno®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (Coruno® 16 mg, once daily)
Trial: 22865782
Drug: Exemestane (EXE)
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane (EXE) treatment
Trial: 12573372
Drug: Intrahepatic arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrahepatic arterial (IHA) chemotherapy (folinic acid 200 mg/m2, fluorouracil 400 mg/m2 over 15 mins and 22‐h infusion 1600 mg/m2, day 1 and 2, repeated every 14 days)
Trial: 12573372
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy (folinic acid 200 mg/m2, fluorouracil bolus 400 mg/m2 and 22‐h infusion 600 mg/m2, day 1 and 2, repeated every 14 days)
Trial: 12573372
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (IHA and intravenous)
Trial: 10386280
Drug: Granisetron‐Droperidol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron‐Droperidol combination
Trial: 1920171
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of heart failure
Trial: 29989335
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300 U/mL (Gla300)
Trial: 29947060
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec (Deg)
Trial: 23141150
Drug: M9L10 (melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M9L10 (melphalan 9 mg/m²/d and lenalidomide 10 mg/d)
Trial: 23141150
Drug: M6L10 (melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M6L10 (melphalan 6 mg/m²/d and lenalidomide 10 mg/d)
Trial: 23141150
Drug: M4L15 (melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M4L15 (melphalan 4 mg/m²/d and lenalidomide 15 mg/d)
Trial: 23141150
Drug: M5L10 (melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M5L10 (melphalan 5 mg/m²/d and lenalidomide 10 mg/d)
Trial: 16466606
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg and 40 mg
Trial: 9042047
Drug: Cinalukast 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinalukast 10 mg
Trial: 9042047
Drug: Cinalukast 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinalukast 50 mg
Trial: 9042047
Drug: Cinalukast 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinalukast 200 mg
Trial: 7874603
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (42 micrograms/nostril) administered three times a day for 8 weeks
Trial: 7874603
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered three times a day for 8 weeks
Trial: 24149180
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus cediranib (20 mg)
Trial: 20180668
Drug: Osmotic-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osmotic-release methylphenidate combined with cognitive-behavioral therapy
Trial: 20180668
Drug: Existing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing treatment program sources (treatment program staff, social services, juvenile justice system, mental health clinics)
Trial: 7871046
Drug: 0.28 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.28 g/kg alcohol
Trial: 7871046
Drug: 0.36 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.36 g/kg alcohol
Trial: 7871046
Drug: 0.54 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.54 g/kg alcohol
Trial: 7871046
Drug: 0.72 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.72 g/kg alcohol
Trial: 21708838
Drug: 0.00 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.00 g/kg (placebo)
Trial: 7871046
Drug: Higher alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher alcohol doses
Trial: 27061779
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg) administered at 01:00, 03:00, 05:00, and 07:00 on both nights (total of 800 mg/night)
Trial: 27061779
Drug: Placebo gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gum administered at 01:00, 03:00, 05:00, and 07:00 on both nights
Trial: 25499937
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg self-administered via single 1 mL prefilled pen every 2 weeks (increased to 150 mg every 2 weeks at week 12 depending on LDL-C level)
Trial: 25499937
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day (statin rechallenge)
Trial: 22930768
Drug: Tapered OSSEOTITE
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapered OSSEOTITE NT implants
Trial: 22930768
Drug: Straight-walled OSSEOTITE
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Straight-walled OSSEOTITE implants
Trial: 10506405
Drug: Ty21a enteric-coated
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ty21a enteric-coated capsules (3 doses, every other day schedule)
Trial: 10506405
Drug: Ty21a liquid
RxNorm normalized name: Salmonella typhi Ty21a live antigen 2000000000 UNT [Vivotif]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ty21a liquid formulation (3 doses, every other day schedule)
Trial: 8777997
Drug: Acarbose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (100 mg orally)
Trial: 8273531
Drug: Hypnotic doses
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic doses of propofol
Trial: 2446752
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2 at 3-week intervals)
Trial: 2446752
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2 at 3-week intervals) and Tamoxifen (10 mg twice per day)
Trial: 26917606
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 500 μg twice daily
Trial: 25691681
Drug: Sucroferric oxyhydroxide
RxNorm normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucroferric oxyhydroxide 1.0-3.0 g/day (2-6 tablets/day)
Trial: 25691681
Drug: Sevelamer 2.4-14.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevelamer 2.4-14.4 g/day (3-18 tablets/day)
Trial: 18258750
Drug: Taranabant (0.5-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant (0.5-600 mg)
Trial: 18258750
Drug: Taranabant (0.5-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant (0.5-600 mg) with high-fat meal
Trial: 17063345
Drug: Sibutramine in
RxNorm normalized name: Product containing sibutramine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine in combination with diet and lifestyle advice
Trial: 10570622
Drug: Entacapone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone (200 mg, 2 to 10 times daily) coadministered with levodopa/carbidopa or levodopa/benserazide
Trial: 2745343
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl infusion (mean volume 1,280.3 +/- 107.3 ml)
Trial: 333077
Drug: Liberal sodium
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal sodium bicarbonate treatment (5 to 15 mEq bicarbonate/dl 10% glucose)
Trial: 333077
Drug: Restricted sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted sodium bicarbonate treatment
Trial: 31370154
Drug: FFE-50× at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFE-50× at 200 mg
Trial: 31370154
Drug: FFE-10× at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFE-10× at 1200 mg
Trial: 31370154
Drug: FFE-50× at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFE-50× at 100 mg
Trial: 31370154
Drug: FFE-10× at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFE-10× at 600 mg
Trial: 28365118
Drug: Moderate grain
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 3 days (MGD3)
Trial: 28365118
Drug: Moderate grain
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 7 days (MGD7)
Trial: 28365118
Drug: Moderate grain
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 14 days (MGD14)
Trial: 28365118
Drug: Moderate grain
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 21 days (MGD21)
Trial: 28365118
Drug: Moderate grain
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement)
Trial: 28365118
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (CTRL; 92% chopped grass hay and 8% mineral and vitamin supplement on a dry matter basis)
Trial: 25262164
Drug: Chemo-immunotherapy (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-immunotherapy (group A)
Trial: 19702088
Drug: Chemotherapy (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (group B)
Trial: 23088524
Drug: Hyaluronan gels
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronan gels applied during the first 2 weeks after SRP (n = 17)
Trial: 16770728
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (200 mg daily for 6 weeks)
Trial: 16770728
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 6 weeks)
Trial: 8996149
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with six cycles of 5FU (425 mg/m2) plus leucovorin (20 mg/m2) by rapid intravenous injection daily for 5 consecutive days every 4 to 5 weeks
Trial: 21199130
Drug: 0.5 mg·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg·kg(‐1) ketorolac IV
Trial: 21199130
Drug: 1 mg·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg·kg(‐1) ketorolac IV
Trial: 16946218
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol 400 mug
Trial: 16946218
Drug: Rectal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal misoprostol 400 mug
Trial: 10776826
Drug: Clodronate 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1600 mg/day orally
Trial: 12027844
Drug: Mivacurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium 0.2 mg/kg
Trial: 1598824
Drug: Tablet A
RxNorm normalized name: tablet administration aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet A (300 mg ofloxacin)
Trial: 1598824
Drug: Tablet B
RxNorm normalized name: Biaxin 4 Tablet Blister Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet B (300 mg ofloxacin)
Trial: 27305037
Drug: Hypofractionated whole‐breast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated whole‐breast irradiation (HF‐WBI) at a dose of 42.56 grays in 16 fractions plus a tumor bed boost
Trial: 27305037
Drug: Conventionally fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally fractionated whole‐breast irradiation (CF‐WBI) at a dose of 50 grays in 25 fractions plus a tumor bed boost
Trial: 27305037
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (CF‐WBI and HF‐WBI)
Trial: 21867844
Drug: simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg/ezetimibe 10 mg
Trial: 16436852
Drug: Levobupivacaine (0.25%)
RxNorm normalized name: levobupivacaine 0.25 MG/ML
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levobupivacaine (0.25%) bolus with saline infusion (group I)